Real-life effectiveness of afatinib versus gefitinib in patients with non-small-cell lung cancer: a Czech multicentre study

M Svaton, M Bratová, O Fischer, J Krejci… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

M Svaton, M Bratová, O Fischer, J Krejci, L Koubkova… - 2021 - med.muni.cz
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

M Svaton, M Bratova, O Fischer, J Krejci… - Anticancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Background/aim We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …

[PDF][PDF] Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

M SVATON, M BRATOVA, O FISCHER… - ANTICANCER …, 2021 - ar.iiarjournals.org
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

M Svaton, M Bratová, O Fischer, J Krejci, L Koubkova… - 2021 - muni.cz
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.

M Svaton, M Bratova, O Fischer, J Krejci… - Anticancer …, 2021 - europepmc.org
Results ORR did not differ in any group or subgroup. Among all patients, we observed
significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 …

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

M Svaton, M Bratová, O Fischer, J Krejci, L Koubkova… - 2021 - med.muni.cz
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

M Svaton, M Bratová, O Fischer, J Krejci, L Koubkova… - 2021 - muni.cz
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …